Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Recommendation of "Reduce" by Brokerages

Key Points

• Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received an average recommendation of "Reduce" from brokerages, with five analysts rating the stock as a sell, three as hold, and two as buy.
• Shares of Integra recently traded up 5.9%, reaching a price of $14.80 and reflecting an average price target among analysts of $18.43 over the next year.
• The company reported a negative net margin of 30.87% in its latest earnings, although it surpassed analysts' expectations by posting $0.45 EPS for the quarter.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) have been given an average recommendation of "Reduce" by the ten brokerages that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $18.4286.

Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of Integra LifeSciences in a research report on Saturday, September 27th.

Integra LifeSciences Trading Up 5.9%

Shares of NASDAQ:IART traded up $0.83 on Friday, reaching $14.80. 1,068,177 shares of the company traded hands, compared to its average volume of 1,115,782. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The business's 50-day simple moving average is $14.19 and its 200 day simple moving average is $14.67. The stock has a market capitalization of $1.15 billion, a P/E ratio of -2.27 and a beta of 1.21. Integra LifeSciences has a 52 week low of $11.06 and a 52 week high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. During the same quarter in the previous year, the firm posted $0.63 EPS. The firm's revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IART. GAMMA Investing LLC grew its holdings in Integra LifeSciences by 55.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company's stock worth $37,000 after buying an additional 913 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in Integra LifeSciences by 205.9% during the second quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock worth $38,000 after buying an additional 2,108 shares during the last quarter. Osaic Holdings Inc. grew its position in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Integra LifeSciences in the second quarter valued at about $73,000. Finally, EMC Capital Management bought a new position in shares of Integra LifeSciences in the second quarter valued at approximately $75,000. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.